Drug intelligence / Profile preview

CX201

Development stage: Preclinical
Lead developer: Curex
Modality: Small Molecules

Overview

CX201 is a small molecule inhibitor targeting Sterol Regulatory Element-Binding Protein 1 (SREBP1), currently in preclinical development by CureX Biopharma for the treatment of renal cell carcinoma (RCC). SREBP1 is a master transcriptional regulator of lipid homeostasis, and its dysregulation is associated with the metabolic reprogramming observed in various malignancies. By inhibiting SREBP1, CX201 aims to suppress the lipogenic pathways that support tumor cell proliferation and survival, particularly in clear cell renal cell carcinoma where lipid accumulation is a hallmark feature.

Other names: Folate receptor alpha-loaded dendritic cell vaccineFRαDCsMayo Clinic Th17 Dendritic Cell VaccineTh17 dendritic cell vaccineTh-17 dendritic cell vaccineTh 17 dendritic cell vaccineTh17-inducing FRα-loaded DCs

Targets

SREBP-1 / SREBF1 (SREBP-1)

Beyond the preview

Go deeper on CX201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX201.

Explore the full profile